Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 3/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14038167 | 0.81 | ALDH1A1 (0.32) | GAASMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1530667 | 0.80 | CA12 (0.38) | GAACA12CA1CA2CA7 | |
| SCHEMBL1530811 | 0.77 | CA2 (0.36) | GAACA12CA1CA2CA7 | |
| SCHEMBL23056741 | 0.76 | — | — | |
| SCHEMBL14038019 | 0.76 | MAPT (0.42) | GAACA12CA1CA2CA7 | |
| SCHEMBL2227857 | 0.74 | MEN1 (0.33) | KMT2AMEN1 | |
| SCHEMBL1620919 | 0.74 | TLR2 (0.38) | KMT2AMEN1MAPTMAPK1TP53 | |
| SCHEMBL26307870 | 0.74 | TLR2 (0.36) | KMT2AMEN1MAPTMAPK1TP53 | |
| SCHEMBL23071679 | 0.73 | HRH4 (0.31) | — | |
| SCHEMBL5135879 | 0.73 | CA12 (0.32) | GAACA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309730-B1 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | NANOGEN RECOGNOMICS GMBH (DE) | 2008-11-26 | — | — | EP | claimed |
| JP-2004517043-A | — | — | 2004-06-10 | — | — | JP | claimed |
| US-20040087807-A1 | Macromolecules having hydrazide attachment moieties and reagents for their production | SANOFI-AVENTIS S.A. (FR) | 2004-05-06 | — | — | US | claimed |
| EP-1309730-A2 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | Nanogen Recognomics GmbH (DE) | 2003-05-14 | — | — | EP | claimed |
| WO-2002014558-A2 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | NANOGEN RECOGNOMICS GMBH (DE) | 2002-02-21 | — | — | WO | claimed |
| EP-1309730-B1 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | NANOGEN RECOGNOMICS GMBH (DE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1309730-B1 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | NANOGEN RECOGNOMICS GMBH (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-7129229-B2 | Hydrazide building blocks and hydrazide modified biomolecules | NANOGEN RECOGNOMICS GMBH (DE) | 2006-10-31 | — | — | US | disclosed |
| US-20040087807-A1 | Macromolecules having hydrazide attachment moieties and reagents for their production | SANOFI-AVENTIS S.A. (FR) | 2004-05-06 | — | — | US | disclosed |
| EP-1309730-A2 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | Nanogen Recognomics GmbH (DE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014558-A2 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | NANOGEN RECOGNOMICS GMBH (DE) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087807-A1 | Macromolecules having hydrazide attachment moieties and reagents for their production | DNPEP, HPSE, HLCS | GAA 424/4885CA12 688/4885CA1 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.